Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the drug levels of BMS-986166 in healthy male participants.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment Group 1: BMS-986166 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-986166 | Drug | Specified dose on specified days |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Total amount of total radioactivity (TRA) recovered in urine (UR) | Up to 90 days | |
| Total amount of TRA recovered in feces (FR) | Up to 90 days | |
| Total amount of TRA recovered in urine and feces combined (RTotal) | Up to 90 days | |
| Percent of TRA recovered in urine (%UR) | Up to 90 days | |
| Percent of TRA recovered in feces (%FR) | Up to 90 days | |
| Percent of TRA recovered in urine and feces combined (%TOTAL) | Up to 90 days | |
| Maximum observed concentration (Cmax) | Up to 89 days | |
| Time of maximum observed concentration (Tmax) | Up to 89 days | |
| Area under the concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)] | Up to 89 days |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with adverse events (AEs) | Up to 124 days | |
| Number of participants with serious adverse events (SAEs) | Up to 124 days | |
| Number of participants with vital sign abnormalities |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution - 0001 | Madison | Wisconsin | 53704-2526 | United States |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
| BMS Clinical Trial Patient Recruiting | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| C000706608 | BMS-986166 |
| D001726 | Bisacodyl |
| ID | Term |
|---|---|
| D003408 | Cresols |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Bisacodyl |
| Drug |
Specified dose on specified days |
|
|
| Up to 90 days |
| Number of participants with electrocardiogram (ECG) abnormalities | Up to 90 days |
| Number of participants with physical examination abnormalities | Up to 90 days |
| Number of participants with clinical laboratory test abnormalities | Up to 90 days |
| Maximum observed concentration (Cmax) | Up to 89 days |
| Time of maximum observed concentration (Tmax) | Up to 89 days |
| Area under the concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)] | Up to 89 days |
| D006844 |
| Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |